Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Dnorman who wrote (7985)	4/29/2002 10:20:44 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48467

If you liked them at higher prices, you have to love them now...Trying to find bottoms is impossible, I am not even trying to find bottoms with the current market conditions. So, my opinion is if you own them, follow the buy plan, if you don't already own them, perhaps now is the time for a first buy-in...? Or do nothing, up to the individual investor..Remember one thing, we still need a blow-off panic sell-off to reset the markets for a serious, real upmove. NEOT may be due a dcb based the torpedo today...

To: Dnorman who wrote (7985)	5/2/2002 11:48:18 AM
From: Bucky Katt	Read Replies (1) \| Respond to of 48467

GNLB had some interesting news yesterday, surprised no one mentioned it. They still have some things that could turn out to be big in the fire... The problem is bio-tech is an unloved sector at this time, which is good & bad..Good time to buy, bad if you hold from higher (much) levels. GNLB is ok technically. Genelabs Technologies, Inc. (Nasdaq: GNLB - news) announced today that it has entered into a collaboration with the University of Iowa Research Foundation (UIRF) to study the impact of the hepatitis G virus (HGV, also known as GB virus C, or GBV-C) on human immunodeficiency virus (HIV) infection. On September 6, 2001, Jack T. Stapleton, M.D., Professor of Medicine at the University of Iowa Roy J. and Lucille A. Carver College of Medicine and Director of the Helen C. Levitt Center for Viral Pathogenesis and Disease, and his colleagues published "Effect of Coinfection with GB Virus C on Survival Among Patients with HIV Infection" in the "New England Journal of Medicine" (Xiang, et. al., NEJM 2001; 345:707-714). Dr. Stapleton's research showed that patients infected with both HIV and GBV-C had a significantly reduced mortality rate compared to those infected only with HIV. Mortality of HIV-infected patients over the 4.1-year mean duration of the study was 28.5% for those with an HGV infection compared to 56.4% for those without HGV infection (p<0.001). This study confirmed previous reports suggesting delayed progression of HIV in patients coinfected with HGV and, furthermore, found that the infectious HGV clone developed by the University of Iowa research group inhibited the growth of HIV in a cell culture model. Dr. Stapleton stated, "Our findings may have implications for future treatments for HIV. I am pleased to be working with Genelabs and look forward to expanding upon our studies elucidating the role HGV may play in increasing survival of HIV-infected patients." Through the collaboration, Genelabs has granted UIRF a nonexclusive research license to Genelabs' HGV patent portfolio and the parties have exchanged research materials. Because of the potential importance of the University of Iowa's observations showing improved survival for HIV patients who also have an HGV co-infection, UIRF and Genelabs will make research licenses and materials available at no cost to other academic institutions interested in further scientific research in this area. Genelabs scientists first discovered HGV, which is transmitted by blood and other bodily fluids, while seeking to identify what was then an unknown hepatitis virus. Patents covering the HGV genome, peptides and their uses have issued to Genelabs. Since the discovery of HGV was announced by Genelabs in 1995, HGV infection has not been associated with any significant disease. The virus has been reported to be found in approximately 2 percent of all blood donated in the United States, in 15 percent of people infected with hepatitis C, and as high as 40 percent of people infected with HIV. Genelabs has previously granted diagnostics licenses for HGV to Boehringer Mannheim (now Roche Diagnostics), Chiron Corporation and Ortho Diagnostic Systems. Genelabs retains all other commercial rights to its discovery of HGV.